We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HPV16 E6‐antibody associated risk of oropharyngeal cancer increases by calendar‐time: A nested case‐control study.
- Authors
Lehtinen, Matti; Butt, Julia; Gray, Penelope; Brenner, Nicole; Eriksson, Tiina; Lehtinen, Tuomas; Luostarinen, Tapio; Schroeder, Lea; Surcel, Heljä‐Marja; Mäkitie, Antti; Pimenoff, Ville N.; Waterboer, Tim
- Abstract
HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study Abbreviations CL confidence limits FMC Finnish Maternity Cohort HPV human papillomavirus ICD 10 International Classification of Diseases, Tenth Revision MFI median fluorescence intensity OPC oropharyngeal cancer OPSCC oropharyngeal squamous cell carcinoma OR odds ratio RR relative risk During the last 40 years the incidence of oropharyngeal cancer (OPC), especially that of oropharyngeal squamous cell carcinoma (OPSCC) has increased in many Western countries.[1] This is mostly due to the human papillomavirus type 16 epidemic[2] which, in the absence of preventive measures against OPC has resulted in its incidence now exceeding that of cervical cancer.[3] Depending on calendar-time and ethnicity, HPV16 E6 antibodies are associated with 20- to 270-fold relative risk (RR) of OPSCC.[4] Among OPSCC cases prediagnostic HPV16 E6 antibodies became two to three times more prevalent between the early 1990s and 2010.[4] The highest E6 seropositivity among OPSCC cases of 68% was observed in cases with <5 years lead time between serum sampling and an OPSCC diagnosis made after the year 2005.[4] Sensitivity/specificity of HPV16 E6 antibodies in the identification of overt, HPV-driven OPSCC are excellent and exceed 90% and 95%.[5] In a number of OPSCC cases E6 antibodies are positive up to three decades before diagnosis.[4] However, for fertile-aged women affected by the silent HPV16 epidemic since the late 1980s[2] data on the E6 antibody-specific risks are scarce. The firm association between HPV16 and oropharyngeal squamous cell carcinoma will eventually be alleviated by gender-neutral HPV vaccination.[1] In the meantime, middle-aged birth cohorts which are beyond prophylactic vaccination age may be screened for oropharyngeal cancer using HPV16 E6 antibodies.
- Subjects
OROPHARYNGEAL cancer; DISEASE risk factors; GENITAL warts; CASE-control method; HUMAN papillomavirus
- Publication
International Journal of Cancer, 2023, Vol 153, Issue 6, p1313
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.34614